Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by RARECast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RARECast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Eyeing A Challenge to a Blockbuster

40:04
 
Share
 

Manage episode 493644822 series 60790
Content provided by RARECast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RARECast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Tepezza became an instant blockbuster when it hit the market as the first targeted therapy for thyroid eye disease, a rare autoimmune condition that causes eyes to bulge, vision problems, and can lead to long-term damage to the eyes. The success of Tepezza drove Amgen’s $27.8 billion acquisition of Horizon Therapeutics, announced at the end of 2022. Now, Viridian Therapeutics is developing veligrotug, a potential challenger to Tepezza. It’s betting that its demonstrated efficacy, greater dosing convenience, and data showing an ability to resolve double vision associated with thyroid eye disease will make it a fierce competitor. We spoke to Steve Mahoney, CEO of Viridian, about the complexities of thyroid eye disease, the challenges of living with the condition, and why veligrotug has the potential to provide a new alternative for people living with the condition.

  continue reading

551 episodes

Artwork

Eyeing A Challenge to a Blockbuster

RARECast

28 subscribers

published

iconShare
 
Manage episode 493644822 series 60790
Content provided by RARECast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RARECast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Tepezza became an instant blockbuster when it hit the market as the first targeted therapy for thyroid eye disease, a rare autoimmune condition that causes eyes to bulge, vision problems, and can lead to long-term damage to the eyes. The success of Tepezza drove Amgen’s $27.8 billion acquisition of Horizon Therapeutics, announced at the end of 2022. Now, Viridian Therapeutics is developing veligrotug, a potential challenger to Tepezza. It’s betting that its demonstrated efficacy, greater dosing convenience, and data showing an ability to resolve double vision associated with thyroid eye disease will make it a fierce competitor. We spoke to Steve Mahoney, CEO of Viridian, about the complexities of thyroid eye disease, the challenges of living with the condition, and why veligrotug has the potential to provide a new alternative for people living with the condition.

  continue reading

551 episodes

Tất cả các tập

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play